You just read:

XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome

News provided by

XTL Biopharmaceuticals Ltd

Sep 12, 2017, 10:24 ET